Pfizer (PFE) stocks have been in decline for the past two years, offering the opportunity to acquire them at a 50% discount compared to peak prices. They are currently trading even below the lows observed in 2013. Without delving into the merits or drawbacks of Pfizer vaccines, I find it noteworthy that stock prices have reached a support level at $25.00-28.00, where significant investor interest has been evident. While I'm not overly concerned about achieving new all-time highs this year, I do identify another formidable resistance level at $40.00-50.00 per share. This presents a potential return of approximately 60%. Seizing this opportunity, I plan to invest in Pfizer stocks at their current prices.